CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster ...
Cognito Therapeutics has spent the better part of the last decade developing neuromodulation technology that it claims could stop and even reverse the progression of Alzheimer’s and other ...
CAMBRIDGE, Mass., March 05, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...
Riding high on early clinical trial results showing that its neuromodulation headset can improve memory and cognition and slow the deterioration of white matter in the brains of people with ...
Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics and West Virginia University’s ...
Cognito Therapeutics has raised $105m to advance the clinical development and commercial preparedness for its Alzheimer’s disease therapeutic. The Massachusetts-based company’s oversubscribed Series C ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#alzheimers--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results